Content area

Abstract

Exosomes, carriers to transfer endogenous molecules, derived from bone marrow-derived mesenchymal stem cells (BMSCs) have been reported to play a role in the progression of bladder cancer. Here we aimed to test the functional mechanism of microRNA-9-3p (miR-9-3p)-containing exosomes derived from BMSCs in bladder cancer. BMSCs were cocultured with bladder cancer cells, and exosomes secreted from BMSCs were identified. Next, the expression of miR-9-3p and endothelial cell-specific molecule 1 (ESM1) in bladder cancer tissues and cells was determined. Then effects of miR-9-3p and ESM1 via BMSC-derived exosomes on bladder cancer cell viability, migration, invasion, and apoptosis were determined by loss- and gain-of-function experiments and on in vivo tumor growth, and metastasis was assessed in nude mice. miR-9-3p expression was decreased and ESM1 was increased in bladder cancer. BMSCs inhibited bladder cancer cell viability, migration, and invasion, and induced apoptosis, whereas the addition of exosome secretion inhibitor GW4869 achieved the opposite effects. Moreover, exosomal miR-9-3p upregulation or ESM1 silencing suppressed bladder cancer cell viability, migration, and invasion; induced cell apoptosis; and inhibited in vivo tumor growth and metastasis. Taken together, BMSC-derived exosomal miR-9-3p suppressed the progression of bladder cancer through ESM1 downregulation, offering a potential novel therapeutic target for bladder cancer therapy.

Details

Title
Exosomal MicroRNA-9-3p Secreted from BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer
Author
Cai, Hongzhou 1 ; Yang, Xuejian 2 ; Gao, Yang 3 ; Xu, Zicheng 1 ; Yu, Bin 1 ; Xu, Ting 1 ; Li, Xiao 1 ; Xu, Weizhang 1 ; Wang, Xinwei 4 ; Hua, Lixin 5 

 Department of Urology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, P.R. China 
 Department of Urology, Suqian First Hospital, Suqian 223800, P.R. China 
 Department of Radiology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, P.R. China 
 Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, P.R. China 
 Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China 
Pages
787-800
Section
Original Article
Publication year
2019
Publication date
Dec 6, 2019
Publisher
Elsevier Limited
e-ISSN
21622531
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2321593111
Copyright
©2019. The Authors